<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01621490</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-038</org_study_id>
    <secondary_id>2012-001840-23</secondary_id>
    <nct_id>NCT01621490</nct_id>
  </id_info>
  <brief_title>PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma</brief_title>
  <acronym>PD-1</acronym>
  <official_title>An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab
      in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood
      and tumor tissues of subjects with advanced melanoma (unresectable or advanced)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allocation:

      Part 1 and 2: Single Arm study

      Part 3 and 4: Randomized Controlled Trial

      Intervention Model:

      Part 1 and 2: Single group: Single arm study

      Part 3 and 4: Parallel: Participants are assigned to one of two or more groups in parallel
      for the duration of the study

      Minimum Age:

      Part 1: 18

      Part 2, 3 and 4: 16
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 27, 2012</start_date>
  <completion_date type="Actual">October 25, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Change From Baseline to Week 7, of Interferon (IFN) and Interferon Gamma (IFN-gamma) Inducible Factors</measure>
    <time_frame>From last non-missing value prior to first dose to week 7 day 1</time_frame>
    <description>Baseline and post-treatment modulation of serum levels of chemokines, cytokines and other immune mediators were assessed by techniques that included ELISA or other multiplex-based assay methods. Primary analysis included IFN-gamma and IFN-gamma inducible factors, including chemokine [C-X-C motif] ligand 9 (CXCL9) and CXCL10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Infiltrating Lymphocytes (TILs) as Measured by Medians in Percent Positive CD8 and Positive CD4 at Baseline and On-treatment Biopsy, Both Using the Mosaic Singleplex IHC Assay</measure>
    <time_frame>From last non-missing value prior to first dose to week 4 day 1</time_frame>
    <description>Biomarkers examined were percent positive CD8 and percent positive CD4, both using the Mosaic Singleplex IHC assay. Analyses are presented with the medians at baseline and on-treatment, rather than the median change because the baseline values differed across groups. Baseline was defined as the last non-missing value on or prior to the first dose of study therapy. Biopsies were also collected on treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Nivolumab, Ipilimumab and Nivolumab in Combination With Ipilimumab as Measured by the Number of Deaths and AEs</measure>
    <time_frame>Includes events reported between first dose and up to 100 days after last dose of study medication.</time_frame>
    <description>The assessment of safety was based on frequency of deaths, AEs, SAEs, AEs leading to discontinuation of study drug, and abnormalities in specific clinical laboratory assessments. AEs were coded using the MedDRA Version 20.1 AEs and laboratory values were graded for severity according to the NCI CTCAE version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Nivolumab, Ipilimumab and Nivolumab in Combination With Ipilimumab as Measured by SAEs and AEs Leading to Discontinuation of Study Drug.</measure>
    <time_frame>From enrollment to 100 days after the last dose date</time_frame>
    <description>The assessment of safety was based on frequency of SAEs and AEs leading to discontinuation of study drug. AEs were coded using the MedDRA Version 20.1 AEs and laboratory values were graded for severity according to the NCI CTCAE version 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Laboratory Abnormalities in Specific Liver Tests</measure>
    <time_frame>101-120 days after last dose.</time_frame>
    <description>Abnormalities in hepatic parameters measured included those in aspartate aminotransferase (AST), alanine aminotransferase (ALT)and total bilirubin, with respect to upper limit of normal (ULN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Laboratory Abnormalities in Specific Thyroid Tests</measure>
    <time_frame>101-120 days after last dose.</time_frame>
    <description>Abnormalities in thyroid parameters measured included those in thyroid stimulating hormone (TSH) levels with respect to upper limit of normal (ULN) and lower limit of normal (LLN)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Objective Response Rate (ORR)</measure>
    <time_frame>Approximately every 8 weeks until disease progression and in follow-up if no progression</time_frame>
    <description>The objective response rate (ORR) was defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects in the population of interest (eg, all treated subjects or response-evaluable subjects). The BOR was defined as the subject's best response designation, over the study as a whole, recorded between the date of first study drug administration and the date of objectively documented progression per RECIST 1.1, with subsequent confirmation, or date of subsequent anti-cancer therapy, whichever occurred first in the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Median Duration of Response (mDOR)</measure>
    <time_frame>2 years from the first dose of treatment</time_frame>
    <description>Median duration of response (mDOR) was calculated for subjects with BOR of CR or PR only, and is defined as time between the date of first documented objective response and the date of the first subsequent disease progression or death, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Median Time to Response (mTTR)</measure>
    <time_frame>2 years from the first dose of treatment</time_frame>
    <description>Median time to response (mTTR) for a participant with a BOR of CR or PR is defined as the time from the first dosing date to the date of the first documented objective response (CR or PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Progression Free Survival Rate (PFSR)</measure>
    <time_frame>2 years from the first dose of treatment</time_frame>
    <description>The progression free survival rate (PFSR) for a subject was defined as the time from the date of first dose of study medication to the date of the first documented disease progression, or death due to any cause, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Number of Serum Anti-drug Antibody (ADA) Positive Participants and the Number of Neutralizing ADA Positive Participants</measure>
    <time_frame>Up to follow-up visit 2 (101-120 days since last treatment)</time_frame>
    <description>Time Frame: Part 1: Day 1, Day 15, Day 43 of cycle 1, Day 1 of cycle 2, Day 15 of cycle 3, every 16 weeks after cycle 3 up to 2 years, follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment) Part 2, 3 and 4: Weeks 1, 3, 4, 7, 9, 10, 13, 25, 53, 79, 95 follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Objective Response Rate (PD-L1 ORR)</measure>
    <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
    <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The objective response rate (ORR) was defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects in the population of interest (all response-evaluable participants).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as the Duration of Response (PD-L1 DOR)</measure>
    <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
    <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. Median duration of response (mDOR) was calculated for all response-evaluable participants with best overall response of CR or PR only, and is defined as time between the date of first documented objective response and the date of the first subsequent disease progression or death, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Progression Free Survival (PD-L1 PFS)</measure>
    <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
    <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The progression free survival rate (PFSR) for a subject was defined as the time from the date of first dose of study medication to the date of the first documented disease progression, or death due to any cause, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Overall Survival Rate (PD-L1 OSR)</measure>
    <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
    <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The overall survival rate (OSR) for a subject was defined as the time from the date of first dose of study medication to the date of death for any cause. A subject who had not died was censored at last known date alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Overall Survival Rate (OSR)</measure>
    <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
    <description>The proportion of subjects surviving to time t, where t is a specific length of time, eg, 12 months, which was determined by the available data for final analysis and was documented in the DPP. The proportion was calculated by the product-limit method (Kaplan-Meier estimate), which takes into account censored data. The overall survival rate (OSR) for a subject was defined as the time from the date of first dose of study medication to the date of death for any cause. A subject who had not died was censored at last known date alive</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Advanced Melanoma</condition>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Part 1-Cohort 1 and 2: Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3-Arm B: Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4-Arm D: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4-Arm E: Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg solution intravenously as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Part 1-Cohort 1 and 2: Nivolumab</arm_group_label>
    <arm_group_label>Part 2-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 3-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 3-Arm B: Nivolumab</arm_group_label>
    <arm_group_label>Part 4-Arm D: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 4-Arm E: Nivolumab</arm_group_label>
    <other_name>BMS-936558 (MDX1106)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <arm_group_label>Part 2-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 3-Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Part 4-Arm D: Nivolumab + Ipilimumab</arm_group_label>
    <other_name>BMS734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Part 1:

        Inclusion Criteria:

          -  Men and women &gt;18 years

          -  Eastern Cooperative Oncology Group (ECOG) status = 0 to 1

          -  Subjects with unresectable Stage III or IV melanoma who are either refractory or
             intolerant to, or have refused standard therapy for treatment of metastatic melanoma

          -  Subject must have histologic or cytologic confirmation of advanced melanoma

          -  Subjects must have at least one measurable lesion at baseline by computed tomography
             (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid
             Tumors (RECIST) 1.1 criteria

          -  Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical
             risk and must consent to pre- and post-treatment biopsies

        Exclusion Criteria:

          -  Active or progressing brain metastases

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active or history of autoimmune disease

          -  Positive test for human immunodeficiency virus (HIV) 1&amp;2 or known acquired
             immunodeficiency syndrome (AIDS)

          -  History of any hepatitis

          -  Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
             including but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137,
             anti-OX-40,and anti-CD40 antibodies. However, half the patients must have progressed
             on anti Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) monoclonal antibody
             therapy

        Part 2, 3 and 4:

        Inclusion Criteria

          -  Men and women &gt;16 years

          -  Eastern Cooperative Oncology Group (ECOG) status = 0 to 1

          -  Subjects with unresectable Stage III or IV melanoma who are either refractory or
             intolerant to, or have refused standard therapy for treatment of metastatic melanoma

          -  Subjects must never received anti-CTLA4 therapy

          -  Subjects must have histologic or cytologic confirmation of advanced melanoma

          -  Subjects must have at least two measurable lesions at baseline by CT or MRI as per
             RECIST 1.1 criteria

          -  Subjects must have at least 1 tumor site that can be biopsied at acceptable clinical
             risk and must consent to pre- and post-treatment biopsies

          -  Subjects in Part 4 must have brain metastases

        Exclusion Criteria

          -  Active or progressing brain metastases (except for Part 4 subjects)

          -  Other concomitant malignancies (with some exceptions per protocol)

          -  Active or history of autoimmune disease

          -  Positive test for HIV 1&amp;2 or known AIDS

          -  History of any hepatitis

          -  Prior therapy with any antibody/drug that targets the T cell coregulatory proteins,
             including but not limited to, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137,
             anti-OX-40,and anti-CD40 antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucla</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (BIDMC)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31192</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 14, 2012</study_first_submitted>
  <study_first_submitted_qc>June 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2012</study_first_posted>
  <results_first_submitted>September 12, 2018</results_first_submitted>
  <results_first_submitted_qc>November 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 3, 2019</results_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01621490/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT01621490/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>227 participants were enrolled; 55 did not enter the treatment period: 41 did not meet study criteria; 6 other; 5 withdrew consent; 1 adverse events; 2 deaths. 172 entered the treatment period.2 were not treated;1 received ipilimumab monotherapy prior to the closure of Arm C; 1 received an unplanned treatment;168 were treated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>N3 60 M Naive</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; 30M = 30 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
        </group>
        <group group_id="P2">
          <title>N3 60M Prog</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; PROG = Anti-CTLA4 Progressed</description>
        </group>
        <group group_id="P3">
          <title>N1 60M + I3 90M, W2</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W2 = Week 2 Biopsy</description>
        </group>
        <group group_id="P4">
          <title>N1 60M + I3 90M, W4</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W4 = Week 4 Biopsy</description>
        </group>
        <group group_id="P5">
          <title>N1 60M +I3 90M, WU</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; WU = Unknown Week Biopsy;</description>
        </group>
        <group group_id="P6">
          <title>N1 30M + I3 30M Non-BM</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
        <group group_id="P7">
          <title>N3 30M Non-BM</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg;30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
        <group group_id="P8">
          <title>N1 30M +I3 30M BM</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
        <group group_id="P9">
          <title>N3 30M BM</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="11"/>
                <participants group_id="P8" count="10"/>
                <participants group_id="P9" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Participant completed treatment</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient could not travel</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Maximum clinical benefit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject request to discontinue study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse event unrelated to study drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study drug toxicity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Grade 4 Lipase elevation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>BMS informed of patient status</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Documented disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient reached treatment 2 yr limit</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Clinical deterioration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Complete response</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient delayed due to toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N3 60 M Naive</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; 30M = 30 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
        </group>
        <group group_id="B2">
          <title>N3 60M Prog</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; PROG = Anti-CTLA4 Progressed;</description>
        </group>
        <group group_id="B3">
          <title>N1 60M + I3 90M, W2</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W2 = Week 2 Biopsy</description>
        </group>
        <group group_id="B4">
          <title>N1 60M + I3 90M, W4</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W4 = Week 4 Biopsy</description>
        </group>
        <group group_id="B5">
          <title>N1 60M +I3 90M, WU</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; WU = Unknown Week Biopsy;</description>
        </group>
        <group group_id="B6">
          <title>N1 30M + I3 30M Non-BM</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
        <group group_id="B7">
          <title>N3 30M Non-BM</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg;30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
        <group group_id="B8">
          <title>N1 30M +I3 30M BM</title>
          <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
        <group group_id="B9">
          <title>N3 30M BM</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="25"/>
            <count group_id="B7" value="11"/>
            <count group_id="B8" value="10"/>
            <count group_id="B9" value="10"/>
            <count group_id="B10" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="12.49"/>
                    <measurement group_id="B2" value="53.7" spread="15.10"/>
                    <measurement group_id="B3" value="61.0" spread="11.82"/>
                    <measurement group_id="B4" value="58.5" spread="13.29"/>
                    <measurement group_id="B5" value="56.8" spread="9.64"/>
                    <measurement group_id="B6" value="56.9" spread="13.52"/>
                    <measurement group_id="B7" value="51.5" spread="15.55"/>
                    <measurement group_id="B8" value="56.9" spread="9.37"/>
                    <measurement group_id="B9" value="58.9" spread="13.46"/>
                    <measurement group_id="B10" value="55.8" spread="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="167"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Change From Baseline to Week 7, of Interferon (IFN) and Interferon Gamma (IFN-gamma) Inducible Factors</title>
        <description>Baseline and post-treatment modulation of serum levels of chemokines, cytokines and other immune mediators were assessed by techniques that included ELISA or other multiplex-based assay methods. Primary analysis included IFN-gamma and IFN-gamma inducible factors, including chemokine [C-X-C motif] ligand 9 (CXCL9) and CXCL10</description>
        <time_frame>From last non-missing value prior to first dose to week 7 day 1</time_frame>
        <population>All response evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>Treatment Group: Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>Treatment Group: Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Progressed</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M</title>
            <description>Treatment Group: Part 2: Nivolumab 1 mg/kg 60 Minute Infusion + Ipilimumab 3 mg/kg 90 Minute</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M Non-BM</title>
            <description>Treatment Group: Part 3: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M Non-BM</title>
            <description>Treatment Group: Part 3: Nivolumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>Treatment Group: Part 4: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>Treatment Group: Part 4: Nivolumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O8">
            <title>N1+ I3 Non-BM</title>
            <description>Treatment Group: Part 2+3: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Non-Brain Metastases</description>
          </group>
          <group group_id="O9">
            <title>Naive Nivo Mono</title>
            <description>Nivolumab Monotherapy CTLA-4 Naive</description>
          </group>
          <group group_id="O10">
            <title>All Nivo</title>
            <description>Treatment Group: All Nivolumab Monotherapy</description>
          </group>
          <group group_id="O11">
            <title>All Combo</title>
            <description>Treatment Group: All Combination Therapy</description>
          </group>
          <group group_id="O12">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline to Week 7, of Interferon (IFN) and Interferon Gamma (IFN-gamma) Inducible Factors</title>
          <description>Baseline and post-treatment modulation of serum levels of chemokines, cytokines and other immune mediators were assessed by techniques that included ELISA or other multiplex-based assay methods. Primary analysis included IFN-gamma and IFN-gamma inducible factors, including chemokine [C-X-C motif] ligand 9 (CXCL9) and CXCL10</description>
          <population>All response evaluable participants</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="50"/>
                <count group_id="O9" value="58"/>
                <count group_id="O10" value="98"/>
                <count group_id="O11" value="58"/>
                <count group_id="O12" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFN-gamma Simoa</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="77"/>
                    <count group_id="O11" value="37"/>
                    <count group_id="O12" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0130" spread="0.1740"/>
                    <measurement group_id="O2" value="0.0320" spread="0.0817"/>
                    <measurement group_id="O3" value="0.2310" spread="0.4528"/>
                    <measurement group_id="O4" value="0.1600" spread="1.2047"/>
                    <measurement group_id="O5" value="0.0520" spread="0.1207"/>
                    <measurement group_id="O6" value="0.0950" spread="1.5082"/>
                    <measurement group_id="O7" value="0.0375" spread="0.1868"/>
                    <measurement group_id="O8" value="0.2200" spread="0.8198"/>
                    <measurement group_id="O9" value="0.0130" spread="0.1674"/>
                    <measurement group_id="O10" value="0.0240" spread="0.1373"/>
                    <measurement group_id="O11" value="0.1520" spread="1.0023"/>
                    <measurement group_id="O12" value="0.0515" spread="0.5944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXL9 (aka MIG)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="77"/>
                    <count group_id="O11" value="37"/>
                    <count group_id="O12" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1105.0" spread="10467.4"/>
                    <measurement group_id="O2" value="1890.0" spread="8706.0"/>
                    <measurement group_id="O3" value="4680.0" spread="18096.9"/>
                    <measurement group_id="O4" value="3542.0" spread="12133.1"/>
                    <measurement group_id="O5" value="-29.0" spread="1684.2"/>
                    <measurement group_id="O6" value="5692.0" spread="6796.0"/>
                    <measurement group_id="O7" value="3610.0" spread="2197.4"/>
                    <measurement group_id="O8" value="458.5" spread="1651.0"/>
                    <measurement group_id="O9" value="1056.5" spread="9167.8"/>
                    <measurement group_id="O10" value="1235.0" spread="8984.2"/>
                    <measurement group_id="O11" value="4680.0" spread="14792.5"/>
                    <measurement group_id="O12" value="2027.0" spread="11491.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CXL10 (aka IP10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="44"/>
                    <count group_id="O10" value="77"/>
                    <count group_id="O11" value="37"/>
                    <count group_id="O12" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.0" spread="514.1"/>
                    <measurement group_id="O2" value="160.0" spread="539.9"/>
                    <measurement group_id="O3" value="684.0" spread="2563.1"/>
                    <measurement group_id="O4" value="934.5" spread="2842.0"/>
                    <measurement group_id="O5" value="26.0" spread="172.7"/>
                    <measurement group_id="O6" value="514.0" spread="612.3"/>
                    <measurement group_id="O7" value="318.0" spread="354.0"/>
                    <measurement group_id="O8" value="695.0" spread="2627.7"/>
                    <measurement group_id="O9" value="185.0" spread="474.6"/>
                    <measurement group_id="O10" value="184.0" spread="500.7"/>
                    <measurement group_id="O11" value="684.0" spread="2450.6"/>
                    <measurement group_id="O12" value="234.5" spread="1566.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Infiltrating Lymphocytes (TILs) as Measured by Medians in Percent Positive CD8 and Positive CD4 at Baseline and On-treatment Biopsy, Both Using the Mosaic Singleplex IHC Assay</title>
        <description>Biomarkers examined were percent positive CD8 and percent positive CD4, both using the Mosaic Singleplex IHC assay. Analyses are presented with the medians at baseline and on-treatment, rather than the median change because the baseline values differed across groups. Baseline was defined as the last non-missing value on or prior to the first dose of study therapy. Biopsies were also collected on treatment.</description>
        <time_frame>From last non-missing value prior to first dose to week 4 day 1</time_frame>
        <population>Response evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>Treatment Group: Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>Treatment Group: Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Progressed</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M W2</title>
            <description>Treatment Group: Part 2: Nivolumab 1 mg/kg 60 Minute Infusion + Ipilimumab 3 mg/kg 90 Minute Infusion Week 2 Biopsy</description>
          </group>
          <group group_id="O4">
            <title>N1 60M + I3 90M W4</title>
            <description>Treatment Group: Part 2: Nivolumab 1 mg/kg 60 Minute Infusion + Ipilimumab 3 mg/kg 90 Minute Infusion Week 4 Biopsy</description>
          </group>
          <group group_id="O5">
            <title>N1 30M + I3 30M Non-BM</title>
            <description>Treatment Group: Part 3: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O6">
            <title>N3 30M Non-BM</title>
            <description>Treatment Group: Part 3: Nivolumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M + I3 30M BM</title>
            <description>Treatment Group: Part 4: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O8">
            <title>N3 30M BM</title>
            <description>Treatment Group: Part 4: Nivolumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O9">
            <title>Nivo Mono</title>
            <description>Treatment Group: Part 1: Regular Infusion Nivolumab Mono</description>
          </group>
          <group group_id="O10">
            <title>Nivo Mono Reduced Infusion</title>
            <description>Treatment Group: Reduced Infusion Nivolumab Monotherapy</description>
          </group>
          <group group_id="O11">
            <title>Week 2 Biopsy Combo</title>
            <description>Treatment Group: Week 2 Biopsy Combo</description>
          </group>
          <group group_id="O12">
            <title>Week 2 Biopsy Non-BM Combo</title>
            <description>Treatment Group: Week 2 Biopsy Non-Brain Metastases Combo</description>
          </group>
          <group group_id="O13">
            <title>Naive Nivo Mono Non-BM</title>
            <description>Treatment Group: Naive Nivolumab Mono Non-Brain Metastases</description>
          </group>
          <group group_id="O14">
            <title>N1 + I3 Non-BM</title>
            <description>Treatment Group: Part 2+3: Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Non-Brain Metastases</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Infiltrating Lymphocytes (TILs) as Measured by Medians in Percent Positive CD8 and Positive CD4 at Baseline and On-treatment Biopsy, Both Using the Mosaic Singleplex IHC Assay</title>
          <description>Biomarkers examined were percent positive CD8 and percent positive CD4, both using the Mosaic Singleplex IHC assay. Analyses are presented with the medians at baseline and on-treatment, rather than the median change because the baseline values differed across groups. Baseline was defined as the last non-missing value on or prior to the first dose of study therapy. Biopsies were also collected on treatment.</description>
          <population>Response evaluable participants</population>
          <units>Percentage of positive cells</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="48"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="29"/>
                <count group_id="O12" value="26"/>
                <count group_id="O13" value="35"/>
                <count group_id="O14" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent CD8 Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="42"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="29"/>
                    <count group_id="O12" value="26"/>
                    <count group_id="O13" value="31"/>
                    <count group_id="O14" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="10.994"/>
                    <measurement group_id="O2" value="7.230" spread="10.712"/>
                    <measurement group_id="O3" value="3.260" spread="9.259"/>
                    <measurement group_id="O4" value="11.105" spread="9.524"/>
                    <measurement group_id="O5" value="4.700" spread="9.810"/>
                    <measurement group_id="O6" value="5.615" spread="12.475"/>
                    <measurement group_id="O7" value="18.590" spread="8.132"/>
                    <measurement group_id="O8" value="6.135" spread="5.664"/>
                    <measurement group_id="O9" value="6.360" spread="10.727"/>
                    <measurement group_id="O10" value="5.615" spread="11.472"/>
                    <measurement group_id="O11" value="4.700" spread="9.292"/>
                    <measurement group_id="O12" value="4.230" spread="9.401"/>
                    <measurement group_id="O13" value="5.210" spread="11.288"/>
                    <measurement group_id="O14" value="4.230" spread="9.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent positive CD8 Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="8"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="11"/>
                    <count group_id="O11" value="21"/>
                    <count group_id="O12" value="18"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="11.345" spread="21.316"/>
                    <measurement group_id="O5" value="7.970" spread="15.132"/>
                    <measurement group_id="O6" value="10.100" spread="10.909"/>
                    <measurement group_id="O7" value="8.470" spread="7.740"/>
                    <measurement group_id="O8" value="29.735" spread="5.254"/>
                    <measurement group_id="O10" value="10.910" spread="12.387"/>
                    <measurement group_id="O11" value="9.080" spread="17.510"/>
                    <measurement group_id="O12" value="9.125" spread="18.654"/>
                    <measurement group_id="O13" value="10.100" spread="10.909"/>
                    <measurement group_id="O14" value="9.125" spread="18.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent positive CD8 Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="30"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="2"/>
                    <count group_id="O13" value="14"/>
                    <count group_id="O14" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.435" spread="17.108"/>
                    <measurement group_id="O2" value="7.140" spread="25.204"/>
                    <measurement group_id="O4" value="32.455" spread="15.967"/>
                    <measurement group_id="O5" value="37.465" spread="5.706"/>
                    <measurement group_id="O9" value="15.150" spread="21.475"/>
                    <measurement group_id="O11" value="37.465" spread="5.706"/>
                    <measurement group_id="O12" value="37.465" spread="5.706"/>
                    <measurement group_id="O13" value="18.435" spread="17.108"/>
                    <measurement group_id="O14" value="34.785" spread="13.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent CD4 Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="42"/>
                    <count group_id="O10" value="11"/>
                    <count group_id="O11" value="28"/>
                    <count group_id="O12" value="25"/>
                    <count group_id="O13" value="31"/>
                    <count group_id="O14" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.360" spread="1.844"/>
                    <measurement group_id="O2" value="0.600" spread="2.268"/>
                    <measurement group_id="O3" value="0.840" spread="1.852"/>
                    <measurement group_id="O4" value="0.470" spread="3.833"/>
                    <measurement group_id="O5" value="4.155" spread="6.624"/>
                    <measurement group_id="O6" value="4.950" spread="4.992"/>
                    <measurement group_id="O7" value="6.500" spread="8.108"/>
                    <measurement group_id="O8" value="2.780" spread="NA">Upper limit not reached</measurement>
                    <measurement group_id="O9" value="0.375" spread="2.057"/>
                    <measurement group_id="O10" value="4.600" spread="4.807"/>
                    <measurement group_id="O11" value="2.750" spread="5.833"/>
                    <measurement group_id="O12" value="2.610" spread="5.607"/>
                    <measurement group_id="O13" value="0.870" spread="3.727"/>
                    <measurement group_id="O14" value="1.510" spread="6.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent positive CD4 Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="7"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="1"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="10"/>
                    <count group_id="O11" value="20"/>
                    <count group_id="O12" value="17"/>
                    <count group_id="O13" value="9"/>
                    <count group_id="O14" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="4.500" spread="10.741"/>
                    <measurement group_id="O5" value="6.260" spread="8.518"/>
                    <measurement group_id="O6" value="4.210" spread="5.029"/>
                    <measurement group_id="O7" value="6.420" spread="14.778"/>
                    <measurement group_id="O8" value="20.830" spread="NA">Upper limit not reached</measurement>
                    <measurement group_id="O10" value="6.155" spread="6.585"/>
                    <measurement group_id="O11" value="6.125" spread="10.222"/>
                    <measurement group_id="O12" value="5.990" spread="9.602"/>
                    <measurement group_id="O13" value="4.210" spread="5.029"/>
                    <measurement group_id="O14" value="5.990" spread="9.602"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent positive CD4 Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                    <count group_id="O9" value="30"/>
                    <count group_id="O10" value="0"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="2"/>
                    <count group_id="O13" value="14"/>
                    <count group_id="O14" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.585" spread="3.071"/>
                    <measurement group_id="O2" value="1.260" spread="4.641"/>
                    <measurement group_id="O4" value="9.005" spread="13.324"/>
                    <measurement group_id="O5" value="24.520" spread="2.659"/>
                    <measurement group_id="O9" value="1.275" spread="3.921"/>
                    <measurement group_id="O11" value="24.520" spread="2.659"/>
                    <measurement group_id="O12" value="24.520" spread="2.659"/>
                    <measurement group_id="O13" value="1.585" spread="3.071"/>
                    <measurement group_id="O14" value="10.155" spread="12.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Nivolumab, Ipilimumab and Nivolumab in Combination With Ipilimumab as Measured by the Number of Deaths and AEs</title>
        <description>The assessment of safety was based on frequency of deaths, AEs, SAEs, AEs leading to discontinuation of study drug, and abnormalities in specific clinical laboratory assessments. AEs were coded using the MedDRA Version 20.1 AEs and laboratory values were graded for severity according to the NCI CTCAE version 4.0.</description>
        <time_frame>Includes events reported between first dose and up to 100 days after last dose of study medication.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>N3 = Nivolumab 3mg/kg;60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M Non-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M Non-BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N3 60M</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O9">
            <title>N3 30M</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O10">
            <title>N1 30M + I3 30M</title>
            <description>N3 = Nivolumab 3mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion</description>
          </group>
          <group group_id="O11">
            <title>N3 NAIVE</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O12">
            <title>All N3</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O13">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Nivolumab, Ipilimumab and Nivolumab in Combination With Ipilimumab as Measured by the Number of Deaths and AEs</title>
          <description>The assessment of safety was based on frequency of deaths, AEs, SAEs, AEs leading to discontinuation of study drug, and abnormalities in specific clinical laboratory assessments. AEs were coded using the MedDRA Version 20.1 AEs and laboratory values were graded for severity according to the NCI CTCAE version 4.0.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="85"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="35"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="106"/>
                <count group_id="O13" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants who died</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="51"/>
                    <measurement group_id="O9" value="8"/>
                    <measurement group_id="O10" value="14"/>
                    <measurement group_id="O11" value="34"/>
                    <measurement group_id="O12" value="59"/>
                    <measurement group_id="O13" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants who died within 30 days of last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="5"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="5"/>
                    <measurement group_id="O13" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants who died within 100 days of last dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="8"/>
                    <measurement group_id="O12" value="16"/>
                    <measurement group_id="O13" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="85"/>
                    <measurement group_id="O9" value="21"/>
                    <measurement group_id="O10" value="35"/>
                    <measurement group_id="O11" value="62"/>
                    <measurement group_id="O12" value="106"/>
                    <measurement group_id="O13" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Nivolumab, Ipilimumab and Nivolumab in Combination With Ipilimumab as Measured by SAEs and AEs Leading to Discontinuation of Study Drug.</title>
        <description>The assessment of safety was based on frequency of SAEs and AEs leading to discontinuation of study drug. AEs were coded using the MedDRA Version 20.1 AEs and laboratory values were graded for severity according to the NCI CTCAE version 4.0.</description>
        <time_frame>From enrollment to 100 days after the last dose date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M Prog</title>
            <description>Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Progressed</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M</title>
            <description>Part 2: Nivolumab 1 mg/kg 60 Minute Infusion + Ipilimumab 3 mg/kg 90 Minute Infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M Non-BM</title>
            <description>Part 3: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M Non-BM</title>
            <description>Part 3: Nivolumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M I3 30M BM</title>
            <description>Part 4: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>Part 4: Nivolumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O8">
            <title>Nivo Mono</title>
            <description>Part 1: Regular Infusion Nivolumab Mono</description>
          </group>
          <group group_id="O9">
            <title>Reduced Nivo Mono</title>
            <description>Reduced Infusion Nivolumab Mono</description>
          </group>
          <group group_id="O10">
            <title>Reduced Combo</title>
            <description>Reduced Infusion Combo</description>
          </group>
          <group group_id="O11">
            <title>Naive Nivo Mono</title>
            <description>Naive Nivolumab Mono</description>
          </group>
          <group group_id="O12">
            <title>All Nivo Mono</title>
            <description>All Nivolumab Mono</description>
          </group>
          <group group_id="O13">
            <title>All Combo</title>
            <description>All Combinations</description>
          </group>
          <group group_id="O14">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Nivolumab, Ipilimumab and Nivolumab in Combination With Ipilimumab as Measured by SAEs and AEs Leading to Discontinuation of Study Drug.</title>
          <description>The assessment of safety was based on frequency of SAEs and AEs leading to discontinuation of study drug. AEs were coded using the MedDRA Version 20.1 AEs and laboratory values were graded for severity according to the NCI CTCAE version 4.0.</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="85"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="35"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="106"/>
                <count group_id="O13" value="62"/>
                <count group_id="O14" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs by Worst CTC Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="6"/>
                    <measurement group_id="O10" value="19"/>
                    <measurement group_id="O11" value="22"/>
                    <measurement group_id="O12" value="38"/>
                    <measurement group_id="O13" value="39"/>
                    <measurement group_id="O14" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs Leading to Discontinuation by Worst CTC Grade</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="9"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="13"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="13"/>
                    <measurement group_id="O13" value="25"/>
                    <measurement group_id="O14" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Laboratory Abnormalities in Specific Liver Tests</title>
        <description>Abnormalities in hepatic parameters measured included those in aspartate aminotransferase (AST), alanine aminotransferase (ALT)and total bilirubin, with respect to upper limit of normal (ULN)</description>
        <time_frame>101-120 days after last dose.</time_frame>
        <population>Participants with at least one on-treatment measurement of the corresponding laboratory parameter</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M NAIVE</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed</description>
          </group>
          <group group_id="O3">
            <title>N1 60M +I3 90M</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M Non-BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M Non-BM</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases;</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg;30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N3 60M</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O9">
            <title>N3 30M</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion</description>
          </group>
          <group group_id="O10">
            <title>N1 30M + I3 30M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion</description>
          </group>
          <group group_id="O11">
            <title>N3 NAIVE</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O12">
            <title>All N3</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O13">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Laboratory Abnormalities in Specific Liver Tests</title>
          <description>Abnormalities in hepatic parameters measured included those in aspartate aminotransferase (AST), alanine aminotransferase (ALT)and total bilirubin, with respect to upper limit of normal (ULN)</description>
          <population>Participants with at least one on-treatment measurement of the corresponding laboratory parameter</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="85"/>
                <count group_id="O9" value="21"/>
                <count group_id="O10" value="35"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="106"/>
                <count group_id="O13" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT OR AST &gt; 3XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="35"/>
                    <count group_id="O11" value="58"/>
                    <count group_id="O12" value="102"/>
                    <count group_id="O13" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="8"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="6"/>
                    <measurement group_id="O13" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT OR AST&gt; 5XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="35"/>
                    <count group_id="O11" value="58"/>
                    <count group_id="O12" value="102"/>
                    <count group_id="O13" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="3"/>
                    <measurement group_id="O13" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT OR AST&gt; 10XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="35"/>
                    <count group_id="O11" value="62"/>
                    <count group_id="O12" value="102"/>
                    <count group_id="O13" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT OR AST &gt; 20XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="35"/>
                    <count group_id="O11" value="62"/>
                    <count group_id="O12" value="102"/>
                    <count group_id="O13" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOTAL BILIRUBIN &gt; 2XULN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="34"/>
                    <count group_id="O11" value="58"/>
                    <count group_id="O12" value="102"/>
                    <count group_id="O13" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/AST ELEV&gt;3XULN;TOTAL BILIRUBIN&gt;2XULN IN 1 DAY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="34"/>
                    <count group_id="O11" value="58"/>
                    <count group_id="O12" value="102"/>
                    <count group_id="O13" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/AST ELEV&gt;3XULN;TOTAL BILIRUBIN&gt;2XULN IN 30 DAY</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="24"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="10"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="19"/>
                    <count group_id="O10" value="34"/>
                    <count group_id="O11" value="58"/>
                    <count group_id="O12" value="102"/>
                    <count group_id="O13" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="2"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Laboratory Abnormalities in Specific Thyroid Tests</title>
        <description>Abnormalities in thyroid parameters measured included those in thyroid stimulating hormone (TSH) levels with respect to upper limit of normal (ULN) and lower limit of normal (LLN)</description>
        <time_frame>101-120 days after last dose.</time_frame>
        <population>Participants with at least one on-treatment measurement of TSH</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M NAIVE</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed</description>
          </group>
          <group group_id="O3">
            <title>N1 60M +I3 90M</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M Non-BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M Non-BM</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases;</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg;30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N3 60M</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O9">
            <title>N3 30M</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion</description>
          </group>
          <group group_id="O10">
            <title>N1 30M + I3 30M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion</description>
          </group>
          <group group_id="O11">
            <title>N3 NAIVE</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O12">
            <title>All N3</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O13">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Laboratory Abnormalities in Specific Thyroid Tests</title>
          <description>Abnormalities in thyroid parameters measured included those in thyroid stimulating hormone (TSH) levels with respect to upper limit of normal (ULN) and lower limit of normal (LLN)</description>
          <population>Participants with at least one on-treatment measurement of TSH</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="62"/>
                <count group_id="O9" value="19"/>
                <count group_id="O10" value="35"/>
                <count group_id="O11" value="48"/>
                <count group_id="O12" value="81"/>
                <count group_id="O13" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TSH &gt; ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="5"/>
                    <measurement group_id="O10" value="10"/>
                    <measurement group_id="O11" value="14"/>
                    <measurement group_id="O12" value="30"/>
                    <measurement group_id="O13" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt; ULN WITH TSH &lt;= ULN AT BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="7"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="16"/>
                    <measurement group_id="O13" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt;ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE &lt;LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt;ULN WITH ALL OTHER FT3/FT4 TEST VALUES &gt;= LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &gt; ULN WITH FT3/FT4 TEST MISSING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="5"/>
                    <measurement group_id="O11" value="12"/>
                    <measurement group_id="O12" value="28"/>
                    <measurement group_id="O13" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt; LLN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="18"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="14"/>
                    <measurement group_id="O13" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt;LLN WITH TSH &gt;= LLN AT BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="18"/>
                    <measurement group_id="O11" value="10"/>
                    <measurement group_id="O12" value="14"/>
                    <measurement group_id="O13" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt;LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE &gt; ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt;LLN WITH ALL OTHER FT3/FT4 TEST VALUES &lt;= ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="1"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TSH &lt; LLN WITH FT3/FT4 TEST MISSING</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="11"/>
                    <measurement group_id="O11" value="7"/>
                    <measurement group_id="O12" value="11"/>
                    <measurement group_id="O13" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Objective Response Rate (ORR)</title>
        <description>The objective response rate (ORR) was defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects in the population of interest (eg, all treated subjects or response-evaluable subjects). The BOR was defined as the subject's best response designation, over the study as a whole, recorded between the date of first study drug administration and the date of objectively documented progression per RECIST 1.1, with subsequent confirmation, or date of subsequent anti-cancer therapy, whichever occurred first in the study.</description>
        <time_frame>Approximately every 8 weeks until disease progression and in follow-up if no progression</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>N3 = Nivolumab 3mg/kg;60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M Prog</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M+I3 90M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M Non-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M Non-BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases;</description>
          </group>
          <group group_id="O6">
            <title>N3 30M + I3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N1 + I3 Non-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O9">
            <title>N3 Naive</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O10">
            <title>N3 Only</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O11">
            <title>N1 + I3</title>
            <description>All combination treatments</description>
          </group>
          <group group_id="O12">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Objective Response Rate (ORR)</title>
          <description>The objective response rate (ORR) was defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects in the population of interest (eg, all treated subjects or response-evaluable subjects). The BOR was defined as the subject's best response designation, over the study as a whole, recorded between the date of first study drug administration and the date of objectively documented progression per RECIST 1.1, with subsequent confirmation, or date of subsequent anti-cancer therapy, whichever occurred first in the study.</description>
          <population>All treated subjects</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="62"/>
                <count group_id="O10" value="106"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" lower_limit="18.1" upper_limit="48.1"/>
                    <measurement group_id="O2" value="22.7" lower_limit="11.5" upper_limit="37.8"/>
                    <measurement group_id="O3" value="44.4" lower_limit="25.5" upper_limit="64.7"/>
                    <measurement group_id="O4" value="40.0" lower_limit="21.1" upper_limit="61.3"/>
                    <measurement group_id="O5" value="27.3" lower_limit="6.0" upper_limit="61.0"/>
                    <measurement group_id="O6" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O7" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O8" value="42.3" lower_limit="28.7" upper_limit="56.8"/>
                    <measurement group_id="O9" value="35.5" lower_limit="23.7" upper_limit="48.7"/>
                    <measurement group_id="O10" value="30.2" lower_limit="21.7" upper_limit="39.9"/>
                    <measurement group_id="O11" value="46.8" lower_limit="34.0" upper_limit="59.9"/>
                    <measurement group_id="O12" value="36.3" lower_limit="29.0" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Median Duration of Response (mDOR)</title>
        <description>Median duration of response (mDOR) was calculated for subjects with BOR of CR or PR only, and is defined as time between the date of first documented objective response and the date of the first subsequent disease progression or death, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
        <time_frame>2 years from the first dose of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>N3 = Nivolumab 3mg/kg;60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O9">
            <title>N3 NAIVE</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O10">
            <title>All N3</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O11">
            <title>N1 + I3</title>
            <description>All combination treatments</description>
          </group>
          <group group_id="O12">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Median Duration of Response (mDOR)</title>
          <description>Median duration of response (mDOR) was calculated for subjects with BOR of CR or PR only, and is defined as time between the date of first documented objective response and the date of the first subsequent disease progression or death, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="62"/>
                <count group_id="O10" value="106"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.21" lower_limit="5.55" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="5.55" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="5.85" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O4" value="26.25" lower_limit="7.85" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="3.71" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="22.01" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O7" value="20.27" lower_limit="13.57" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="26.25" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O9" value="20.27" lower_limit="11.5" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="13.57" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="26.25" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="22.01" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Median Time to Response (mTTR)</title>
        <description>Median time to response (mTTR) for a participant with a BOR of CR or PR is defined as the time from the first dosing date to the date of the first documented objective response (CR or PR).</description>
        <time_frame>2 years from the first dose of treatment</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>N3 = Nivolumab 3mg/kg;60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O9">
            <title>N3 NAIVE</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O10">
            <title>All N3</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O11">
            <title>N1 + I3</title>
            <description>All combination</description>
          </group>
          <group group_id="O12">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Median Time to Response (mTTR)</title>
          <description>Median time to response (mTTR) for a participant with a BOR of CR or PR is defined as the time from the first dosing date to the date of the first documented objective response (CR or PR).</description>
          <population>All treated participants</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="62"/>
                <count group_id="O10" value="106"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="1.77" upper_limit="5.29"/>
                    <measurement group_id="O2" value="2.78" lower_limit="1.84" upper_limit="14.59"/>
                    <measurement group_id="O3" value="1.41" lower_limit="1.28" upper_limit="1.87"/>
                    <measurement group_id="O4" value="2.51" lower_limit="1.28" upper_limit="2.86"/>
                    <measurement group_id="O5" value="1.41" lower_limit="1.41" upper_limit="6.90"/>
                    <measurement group_id="O6" value="1.71" lower_limit="1.38" upper_limit="7.43"/>
                    <measurement group_id="O7" value="2.14" lower_limit="1.25" upper_limit="4.99"/>
                    <measurement group_id="O8" value="1.41" lower_limit="1.41" upper_limit="2.56"/>
                    <measurement group_id="O9" value="1.87" lower_limit="1.74" upper_limit="3.71"/>
                    <measurement group_id="O10" value="1.87" lower_limit="1.84" upper_limit="3.68"/>
                    <measurement group_id="O11" value="1.45" lower_limit="1.41" upper_limit="2.50"/>
                    <measurement group_id="O12" value="1.87" lower_limit="1.71" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Progression Free Survival Rate (PFSR)</title>
        <description>The progression free survival rate (PFSR) for a subject was defined as the time from the date of first dose of study medication to the date of the first documented disease progression, or death due to any cause, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
        <time_frame>2 years from the first dose of treatment</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>N3 = Nivolumab 3mg/kg;60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O9">
            <title>N3 NAIVE</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O10">
            <title>All N3</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O11">
            <title>N1 + I3</title>
            <description>All combination treatments</description>
          </group>
          <group group_id="O12">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Progression Free Survival Rate (PFSR)</title>
          <description>The progression free survival rate (PFSR) for a subject was defined as the time from the date of first dose of study medication to the date of the first documented disease progression, or death due to any cause, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
          <population>All treated subjects</population>
          <units>Percentage</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="62"/>
                <count group_id="O10" value="106"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.68" lower_limit="1.84" upper_limit="7.36"/>
                    <measurement group_id="O2" value="5.62" lower_limit="1.87" upper_limit="9.66"/>
                    <measurement group_id="O3" value="7.00" lower_limit="1.41" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O4" value="9.69" lower_limit="1.94" upper_limit="29.01"/>
                    <measurement group_id="O5" value="4.93" lower_limit="1.41" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="1.18" upper_limit="NA">Median and upper limit not reached</measurement>
                    <measurement group_id="O7" value="23.00" lower_limit="0.85" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O8" value="7.23" lower_limit="1.94" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O9" value="3.91" lower_limit="1.94" upper_limit="10.58"/>
                    <measurement group_id="O10" value="4.93" lower_limit="2.17" upper_limit="8.77"/>
                    <measurement group_id="O11" value="10.55" lower_limit="2.79" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O12" value="5.78" lower_limit="3.29" upper_limit="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Number of Serum Anti-drug Antibody (ADA) Positive Participants and the Number of Neutralizing ADA Positive Participants</title>
        <description>Time Frame: Part 1: Day 1, Day 15, Day 43 of cycle 1, Day 1 of cycle 2, Day 15 of cycle 3, every 16 weeks after cycle 3 up to 2 years, follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment) Part 2, 3 and 4: Weeks 1, 3, 4, 7, 9, 10, 13, 25, 53, 79, 95 follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment)</description>
        <time_frame>Up to follow-up visit 2 (101-120 days since last treatment)</time_frame>
        <population>A subset of all treated subjects who had a baseline and at least 1 post-baseline ADA assessment for nivolumab and ipilimumab separately</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M NAIVE</title>
            <description>Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>Part 1: Nivolumab 3 mg/kg 60 Minute Infusion Anti-CTLA4 Progressed</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 (Nivo ADA</title>
            <description>Part 2: Nivolumab 1 mg/kg 60 Minute Infusion + Ipilimumab 3 mg/kg 90 Minute</description>
          </group>
          <group group_id="O4">
            <title>N1 60M + I3 90M (Ipi ADA)</title>
            <description>Part 2: Nivolumab 1 mg/kg 60 Minute Infusion + Ipilimumab 3 mg/kg 90 Minute</description>
          </group>
          <group group_id="O5">
            <title>N1 30M + I3 30M Non-BM (Nivo ADA)</title>
            <description>Part 3: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M Non-BM (Ipi ADA)</title>
            <description>Part 3: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M Non-BM</title>
            <description>Part 3: Nivolumab 3 mg/kg 30 Minute Infusion Non-Brain Metastases</description>
          </group>
          <group group_id="O8">
            <title>N1 30M + I3 30M (Nivo ADA)</title>
            <description>Part 4: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O9">
            <title>N1 30M + I3 30M (Ipi ADA)</title>
            <description>Part 4: Nivolumab 1 mg/kg 30 Minute Infusion + Ipilimumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O10">
            <title>N3 30M BM</title>
            <description>Part 4: Nivolumab 3 mg/kg 30 Minute Infusion Brain Metastases</description>
          </group>
          <group group_id="O11">
            <title>Total (Nivo ADA)</title>
            <description>Total (All Nivolumab or Nivolumab + Ipilimumab Treated Subjects with Baseline and at Least One Post-Baseline Assessment)</description>
          </group>
          <group group_id="O12">
            <title>Total (Ipi ADA)</title>
            <description>Total (All Nivolumab or Nivolumab + Ipilimumab Treated Subjects with Baseline and at Least One Post-Baseline Assessment)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Number of Serum Anti-drug Antibody (ADA) Positive Participants and the Number of Neutralizing ADA Positive Participants</title>
          <description>Time Frame: Part 1: Day 1, Day 15, Day 43 of cycle 1, Day 1 of cycle 2, Day 15 of cycle 3, every 16 weeks after cycle 3 up to 2 years, follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment) Part 2, 3 and 4: Weeks 1, 3, 4, 7, 9, 10, 13, 25, 53, 79, 95 follow-up visit 1 (40-60 days after last treatment), and follow-up visit 2 (101-120 days since last treatment)</description>
          <population>A subset of all treated subjects who had a baseline and at least 1 post-baseline ADA assessment for nivolumab and ipilimumab separately</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="10"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="7"/>
                <count group_id="O11" value="154"/>
                <count group_id="O12" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADA positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="42"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="10"/>
                    <count group_id="O9" value="9"/>
                    <count group_id="O10" value="7"/>
                    <count group_id="O11" value="154"/>
                    <count group_id="O12" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="42"/>
                    <measurement group_id="O12" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutralizing ADA positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="7"/>
                    <count group_id="O9" value="0"/>
                    <count group_id="O10" value="1"/>
                    <count group_id="O11" value="42"/>
                    <count group_id="O12" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Objective Response Rate (PD-L1 ORR)</title>
        <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The objective response rate (ORR) was defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects in the population of interest (all response-evaluable participants).</description>
        <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
        <population>All response-evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M NAIVE, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W2 = Week 2 Biopsy;</description>
          </group>
          <group group_id="O4">
            <title>N1 60M + I3 90M, W4</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; 30M = 30 minute infusion; W4 = Week 4 Biopsy;</description>
          </group>
          <group group_id="O5">
            <title>N1 60M + I3 90M, WU</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; WU = Unknown Week Biopsy</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M NON-BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O8">
            <title>N1 30M + I3 30M BM, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O9">
            <title>N3 30M BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O10">
            <title>N3 60M, W4</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; W4 = Week 4 Biopsy</description>
          </group>
          <group group_id="O11">
            <title>N3 30M, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O12">
            <title>N1 + I3, W2</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O13">
            <title>N1 + I3 W2, NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy; BM = Brain metastases</description>
          </group>
          <group group_id="O14">
            <title>N3 NAIVE, NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive; BM = Brain metastases</description>
          </group>
          <group group_id="O15">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O16">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Objective Response Rate (PD-L1 ORR)</title>
          <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The objective response rate (ORR) was defined as the number of subjects with a best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized subjects in the population of interest (all response-evaluable participants).</description>
          <population>All response-evaluable participants</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="75"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="37"/>
                <count group_id="O13" value="33"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="49"/>
                <count group_id="O16" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STTU 1 - 1% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="19.1" upper_limit="63.9"/>
                    <measurement group_id="O2" value="35.3" lower_limit="14.2" upper_limit="61.7"/>
                    <measurement group_id="O3" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O4" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O5" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O6" value="63.6" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O7" value="40.0" lower_limit="5.3" upper_limit="85.3"/>
                    <measurement group_id="O8" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O9" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O10" value="37.8" lower_limit="22.5" upper_limit="55.2"/>
                    <measurement group_id="O11" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O12" value="75.0" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O13" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O14" value="40.0" lower_limit="21.1" upper_limit="61.3"/>
                    <measurement group_id="O15" value="65.4" lower_limit="44.3" upper_limit="82.8"/>
                    <measurement group_id="O16" value="50.7" lower_limit="38.6" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 5% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="12.2" upper_limit="73.8"/>
                    <measurement group_id="O2" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                    <measurement group_id="O3" value="80.0" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O4" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O5" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="71.4" lower_limit="29.0" upper_limit="96.3"/>
                    <measurement group_id="O7" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O8" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O9" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O10" value="36.8" lower_limit="16.3" upper_limit="61.6"/>
                    <measurement group_id="O11" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O12" value="78.6" lower_limit="49.2" upper_limit="95.3"/>
                    <measurement group_id="O13" value="75.0" lower_limit="42.8" upper_limit="94.5"/>
                    <measurement group_id="O14" value="41.7" lower_limit="15.2" upper_limit="72.3"/>
                    <measurement group_id="O15" value="72.2" lower_limit="46.5" upper_limit="90.3"/>
                    <measurement group_id="O16" value="57.1" lower_limit="41.0" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 10% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9" lower_limit="9.9" upper_limit="81.6"/>
                    <measurement group_id="O2" value="20.0" lower_limit="0.5" upper_limit="71.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O5" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O6" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O7" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O8" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O9" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O10" value="33.3" lower_limit="9.9" upper_limit="65.1"/>
                    <measurement group_id="O11" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O12" value="87.5" lower_limit="47.3" upper_limit="99.7"/>
                    <measurement group_id="O13" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O14" value="50.0" lower_limit="15.7" upper_limit="84.3"/>
                    <measurement group_id="O15" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O16" value="63.0" lower_limit="42.4" upper_limit="80.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as the Duration of Response (PD-L1 DOR)</title>
        <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. Median duration of response (mDOR) was calculated for all response-evaluable participants with best overall response of CR or PR only, and is defined as time between the date of first documented objective response and the date of the first subsequent disease progression or death, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
        <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
        <population>All response-evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M NAIVE, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W2 = Week 2 Biopsy;</description>
          </group>
          <group group_id="O4">
            <title>N1 60M + I3 90M, W4</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; 30M = 30 minute infusion; W4 = Week 4 Biopsy;</description>
          </group>
          <group group_id="O5">
            <title>N1 60M + I3 90M, WU</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; WU = Unknown Week Biopsy</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M NON-BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O8">
            <title>N1 30M + I3 30M BM, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O9">
            <title>N3 30M BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O10">
            <title>N3 60M, W4</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; W4 = Week 4 Biopsy</description>
          </group>
          <group group_id="O11">
            <title>N3 30M, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O12">
            <title>N1 + I3, W2</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O13">
            <title>N1 + I3 W2, NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy; BM = Brain metastases</description>
          </group>
          <group group_id="O14">
            <title>N3 NAIVE, NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive; BM = Brain metastases</description>
          </group>
          <group group_id="O15">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O16">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as the Duration of Response (PD-L1 DOR)</title>
          <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. Median duration of response (mDOR) was calculated for all response-evaluable participants with best overall response of CR or PR only, and is defined as time between the date of first documented objective response and the date of the first subsequent disease progression or death, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
          <population>All response-evaluable participants</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="75"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="37"/>
                <count group_id="O13" value="33"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="49"/>
                <count group_id="O16" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STTU 1 - 1% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.21" lower_limit="4.60" upper_limit="18.20"/>
                    <measurement group_id="O2" value="NA" lower_limit="15.57" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="2.96" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O6" value="26.25" lower_limit="8.31" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="3.71" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O8" value="22.01" lower_limit="NA" upper_limit="NA">Upper and lower limits not reached</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O10" value="15.57" lower_limit="11.50" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="3.71" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O12" value="26.25" lower_limit="22.01" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O13" value="NA" lower_limit="8.31" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O14" value="15.21" lower_limit="3.71" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O15" value="NA" lower_limit="26.25" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O16" value="26.25" lower_limit="15.57" upper_limit="NA">Upper limit not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 5% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.36" lower_limit="4.60" upper_limit="15.21"/>
                    <measurement group_id="O2" value="NA" lower_limit="15.57" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="2.96" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O6" value="26.25" lower_limit="8.31" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="3.71" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O8" value="22.01" lower_limit="NA" upper_limit="NA">Upper and lower limits not reached</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O10" value="15.57" lower_limit="4.60" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O12" value="26.25" lower_limit="8.31" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O13" value="NA" lower_limit="2.96" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O14" value="15.21" lower_limit="4.60" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O15" value="NA" lower_limit="8.31" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O16" value="26.25" lower_limit="15.21" upper_limit="NA">Upper limit not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 10% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.21" lower_limit="4.60" upper_limit="15.21"/>
                    <measurement group_id="O2" value="15.57" lower_limit="NA" upper_limit="NA">Upper and lower limits not reached</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="2.96" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="3.71" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O8" value="22.01" lower_limit="NA" upper_limit="NA">Upper and lower limits not reached</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O10" value="15.21" lower_limit="4.60" upper_limit="15.57"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="2.96" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O13" value="NA" lower_limit="2.96" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O14" value="15.21" lower_limit="4.60" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O15" value="NA" lower_limit="2.96" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O16" value="NA" lower_limit="15.21" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Progression Free Survival (PD-L1 PFS)</title>
        <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The progression free survival rate (PFSR) for a subject was defined as the time from the date of first dose of study medication to the date of the first documented disease progression, or death due to any cause, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
        <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
        <population>All response-evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M NAIVE, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W2 = Week 2 Biopsy;</description>
          </group>
          <group group_id="O4">
            <title>N1 60M + I3 90M, W4</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; 30M = 30 minute infusion; W4 = Week 4 Biopsy;</description>
          </group>
          <group group_id="O5">
            <title>N1 60M + I3 90M, WU</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; WU = Unknown Week Biopsy</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M NON-BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O8">
            <title>N1 30M + I3 30M BM, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O9">
            <title>N3 30M BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O10">
            <title>N3 60M, W4</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; W4 = Week 4 Biopsy</description>
          </group>
          <group group_id="O11">
            <title>N3 30M, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O12">
            <title>N1 + I3, W2</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O13">
            <title>N1 + I3 W2, NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy; BM = Brain metastases</description>
          </group>
          <group group_id="O14">
            <title>N3 NAIVE, NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive; BM = Brain metastases</description>
          </group>
          <group group_id="O15">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O16">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Progression Free Survival (PD-L1 PFS)</title>
          <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The progression free survival rate (PFSR) for a subject was defined as the time from the date of first dose of study medication to the date of the first documented disease progression, or death due to any cause, whichever occurred first, if death occurred within 100 days after last dose of study medication.</description>
          <population>All response-evaluable participants</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="75"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="37"/>
                <count group_id="O13" value="33"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="49"/>
                <count group_id="O16" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STTU 1 - 1% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" lower_limit="1.84" upper_limit="15.18"/>
                    <measurement group_id="O2" value="9.66" lower_limit="3.71" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="1.22" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0.85" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="0.76" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O6" value="29.01" lower_limit="1.94" upper_limit="29.01"/>
                    <measurement group_id="O7" value="8.77" lower_limit="1.22" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="23.95" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O10" value="6.24" lower_limit="3.65" upper_limit="17.05"/>
                    <measurement group_id="O11" value="8.77" lower_limit="1.22" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O12" value="29.01" lower_limit="4.17" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O13" value="29.01" lower_limit="3.02" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O14" value="5.36" lower_limit="1.94" upper_limit="10.94"/>
                    <measurement group_id="O15" value="29.01" lower_limit="3.02" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O16" value="10.58" lower_limit="5.62" upper_limit="19.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 5% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" lower_limit="0.33" upper_limit="17.05"/>
                    <measurement group_id="O2" value="19.29" lower_limit="1.77" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="1.22" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="0.85" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper limit and lower limit not reached</measurement>
                    <measurement group_id="O6" value="29.01" lower_limit="1.94" upper_limit="29.01"/>
                    <measurement group_id="O7" value="NA" lower_limit="1.22" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="23.95" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O10" value="7.20" lower_limit="1.87" upper_limit="18.40"/>
                    <measurement group_id="O11" value="NA" lower_limit="1.22" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O12" value="29.01" lower_limit="3.02" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O13" value="29.01" lower_limit="1.94" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O14" value="6.28" lower_limit="1.22" upper_limit="17.05"/>
                    <measurement group_id="O15" value="29.01" lower_limit="3.02" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O16" value="17.05" lower_limit="5.36" upper_limit="29.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 10% Level PD-L1 Status: Met criteria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.36" lower_limit="0.33" upper_limit="18.40"/>
                    <measurement group_id="O2" value="19.29" lower_limit="1.77" upper_limit="19.29"/>
                    <measurement group_id="O3" value="NA" lower_limit="4.17" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="1.64" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="1.94" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="23.95" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O10" value="6.24" lower_limit="1.71" upper_limit="18.40"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Median not reached; Upper and lower limits not reached</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="1.94" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O13" value="NA" lower_limit="1.94" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O14" value="11.20" lower_limit="0.33" upper_limit="NA">Upper limit not reached</measurement>
                    <measurement group_id="O15" value="NA" lower_limit="1.94" upper_limit="NA">Median not reached; Upper limit not reached</measurement>
                    <measurement group_id="O16" value="19.29" lower_limit="5.36" upper_limit="NA">Upper limit not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Overall Survival Rate (PD-L1 OSR)</title>
        <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The overall survival rate (OSR) for a subject was defined as the time from the date of first dose of study medication to the date of death for any cause. A subject who had not died was censored at last known date alive</description>
        <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
        <population>Biomarker evaluable participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M NAIVE, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG, W4</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; W2 = Week 2 Biopsy;</description>
          </group>
          <group group_id="O4">
            <title>N1 60M + I3 90M, W4</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; 30M = 30 minute infusion; W4 = Week 4 Biopsy;</description>
          </group>
          <group group_id="O5">
            <title>N1 60M + I3 90M, WU</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion; WU = Unknown Week Biopsy</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M NON-BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O8">
            <title>N1 30M + I3 30M BM, W2</title>
            <description>Treatment Group: N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O9">
            <title>N3 30M BM, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O10">
            <title>N3 60M, W4</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion; W4 = Week 4 Biopsy</description>
          </group>
          <group group_id="O11">
            <title>N3 30M, W2</title>
            <description>Treatment Group: N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O12">
            <title>N1 + I3, W2</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy</description>
          </group>
          <group group_id="O13">
            <title>N1 + I3 W2, NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; W2 = Week 2 Biopsy; BM = Brain metastases</description>
          </group>
          <group group_id="O14">
            <title>N3 NAIVE, NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive; BM = Brain metastases</description>
          </group>
          <group group_id="O15">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O16">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Association Between Programmed Cell Death Ligand 1 (PD-L1) and Clinical Efficacy Measures Such as Overall Survival Rate (PD-L1 OSR)</title>
          <description>For immunohistochemistry (IHC) measurements, to explore the PD-L1 expression as a potential predictive marker of clinical activity, PD-L1 expression status were derived from percent of tumor cells exhibiting cell surface staining for PD-L1 at baseline and/or in archived biopsy samples using verified and/or validated assays. In the case of multiple specimens, a subject would be identified as PD-L1 expression levels &gt;= x%, where x% can be 10%, 5%, and/or 1% in any of the baseline and/or archived specimens. The association between PD-L1 expression status and/or level and clinical efficacy measures was assessed. The overall survival rate (OSR) for a subject was defined as the time from the date of first dose of study medication to the date of death for any cause. A subject who had not died was censored at last known date alive</description>
          <population>Biomarker evaluable participants</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="3"/>
                <count group_id="O10" value="75"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="37"/>
                <count group_id="O13" value="33"/>
                <count group_id="O14" value="48"/>
                <count group_id="O15" value="49"/>
                <count group_id="O16" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>STTU 1 - 1% Level; PD-L1 : Met criteria 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="65.6" upper_limit="97.4"/>
                    <measurement group_id="O2" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="94.6" lower_limit="80.1" upper_limit="98.6"/>
                    <measurement group_id="O11" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="92.0" lower_limit="71.6" upper_limit="97.9"/>
                    <measurement group_id="O15" value="92.3" lower_limit="72.6" upper_limit="98.0"/>
                    <measurement group_id="O16" value="94.4" lower_limit="85.7" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 1% Level PD-L1 : Met criteria 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="65.6" upper_limit="97.4"/>
                    <measurement group_id="O2" value="94.1" lower_limit="65.0" upper_limit="99.1"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="91.9" lower_limit="76.9" upper_limit="97.3"/>
                    <measurement group_id="O11" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="92.0" lower_limit="71.6" upper_limit="97.9"/>
                    <measurement group_id="O15" value="92.3" lower_limit="72.6" upper_limit="98.0"/>
                    <measurement group_id="O16" value="93.0" lower_limit="83.9" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 1% Level PD-L1: Met criteria 9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="55.1" upper_limit="92.0"/>
                    <measurement group_id="O2" value="88.2" lower_limit="60.6" upper_limit="96.9"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="83.8" lower_limit="67.4" upper_limit="92.4"/>
                    <measurement group_id="O11" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="84.0" lower_limit="62.8" upper_limit="93.7"/>
                    <measurement group_id="O15" value="92.3" lower_limit="72.6" upper_limit="98.0"/>
                    <measurement group_id="O16" value="88.7" lower_limit="78.7" upper_limit="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 1% Level PD-L1 : Met criteria 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="50.0" upper_limit="88.7"/>
                    <measurement group_id="O2" value="70.6" lower_limit="43.1" upper_limit="86.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="73.0" lower_limit="55.6" upper_limit="84.4"/>
                    <measurement group_id="O11" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="76.0" lower_limit="54.2" upper_limit="88.4"/>
                    <measurement group_id="O15" value="92.3" lower_limit="72.6" upper_limit="98.0"/>
                    <measurement group_id="O16" value="81.7" lower_limit="70.6" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 1 - 1% Level PD-L1: Met criteria 24 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="37"/>
                    <count group_id="O11" value="6"/>
                    <count group_id="O12" value="20"/>
                    <count group_id="O13" value="18"/>
                    <count group_id="O14" value="25"/>
                    <count group_id="O15" value="26"/>
                    <count group_id="O16" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="31.3" upper_limit="73.5"/>
                    <measurement group_id="O2" value="44.9" lower_limit="20.7" upper_limit="66.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="77.9" lower_limit="35.4" upper_limit="94.2"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="50.5" lower_limit="33.4" upper_limit="65.3"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O12" value="82.2" lower_limit="53.9" upper_limit="94.0"/>
                    <measurement group_id="O13" value="87.7" lower_limit="58.8" upper_limit="96.8"/>
                    <measurement group_id="O14" value="52.0" lower_limit="31.2" upper_limit="69.2"/>
                    <measurement group_id="O15" value="84.0" lower_limit="62.8" upper_limit="93.7"/>
                    <measurement group_id="O16" value="60.8" lower_limit="48.2" upper_limit="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 5 - 5% Level PD-L1 : Met criteria 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="40.9" upper_limit="94.6"/>
                    <measurement group_id="O2" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O10" value="89.5" lower_limit="64.1" upper_limit="97.3"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="83.3" lower_limit="48.2" upper_limit="95.6"/>
                    <measurement group_id="O15" value="94.4" lower_limit="66.6" upper_limit="99.2"/>
                    <measurement group_id="O16" value="92.9" lower_limit="79.5" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 5 - 5% Level PD-L1: Met criteria 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="40.9" upper_limit="94.6"/>
                    <measurement group_id="O2" value="88.9" lower_limit="43.3" upper_limit="98.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O10" value="84.2" lower_limit="58.7" upper_limit="94.6"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="83.3" lower_limit="48.2" upper_limit="95.6"/>
                    <measurement group_id="O15" value="94.4" lower_limit="66.6" upper_limit="99.2"/>
                    <measurement group_id="O16" value="90.5" lower_limit="76.6" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 5 - 5% Level PD-L1 : Met criteria 9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="40.9" upper_limit="94.6"/>
                    <measurement group_id="O2" value="88.9" lower_limit="43.3" upper_limit="98.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="84.2" lower_limit="58.7" upper_limit="94.6"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="83.3" lower_limit="48.2" upper_limit="95.6"/>
                    <measurement group_id="O15" value="94.4" lower_limit="66.6" upper_limit="99.2"/>
                    <measurement group_id="O16" value="90.5" lower_limit="76.6" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 5 - 5% Level PD-L1 : Met criteria 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="32.9" upper_limit="89.2"/>
                    <measurement group_id="O2" value="66.7" lower_limit="28.2" upper_limit="87.8"/>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O6" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O10" value="68.4" lower_limit="42.8" upper_limit="84.4"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="75" lower_limit="40.8" upper_limit="91.2"/>
                    <measurement group_id="O15" value="94.4" lower_limit="66.6" upper_limit="99.2"/>
                    <measurement group_id="O16" value="83.3" lower_limit="68.2" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 5 - 5% Level PD-L1 : Met criteria 24 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="19"/>
                    <count group_id="O11" value="3"/>
                    <count group_id="O12" value="14"/>
                    <count group_id="O13" value="12"/>
                    <count group_id="O14" value="12"/>
                    <count group_id="O15" value="18"/>
                    <count group_id="O16" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="18.4" upper_limit="75.3"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O3" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O10" value="45.6" lower_limit="22.5" upper_limit="66.1"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O12" value="76.0" lower_limit="42.2" upper_limit="91.6"/>
                    <measurement group_id="O13" value="81.5" lower_limit="43.5" upper_limit="95.1"/>
                    <measurement group_id="O14" value="50.0" lower_limit="20.8" upper_limit="73.6"/>
                    <measurement group_id="O15" value="82.5" lower_limit="54.9" upper_limit="94.0"/>
                    <measurement group_id="O16" value="60.7" lower_limit="44.0" upper_limit="73.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 10 - 10% Level PD-L1 : Met criteria 3 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="25.8" upper_limit="92.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O10" value="83.3" lower_limit="48.2" upper_limit="95.6"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="75.0" lower_limit="31.5" upper_limit="93.1"/>
                    <measurement group_id="O15" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O16" value="92.6" lower_limit="73.5" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 10 - 10% Level PD-L1 : Met criteria 6 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="25.8" upper_limit="92.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O10" value="75.0" lower_limit="40.8" upper_limit="91.2"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="75.0" lower_limit="31.5" upper_limit="93.1"/>
                    <measurement group_id="O15" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O16" value="88.9" lower_limit="69.4" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 10 - 10% Level PD-L1: Met criteria 9 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="25.8" upper_limit="92.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="75.0" lower_limit="40.8" upper_limit="91.2"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="75.0" lower_limit="31.5" upper_limit="93.1"/>
                    <measurement group_id="O15" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O16" value="88.9" lower_limit="69.4" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 10 - 10% Level PD-L1 : Met criteria 12 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4" lower_limit="25.8" upper_limit="92.0"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="58.3" lower_limit="27.0" upper_limit="80.1"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O12" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O13" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O14" value="75.0" lower_limit="31.5" upper_limit="93.1"/>
                    <measurement group_id="O15" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O16" value="81.5" lower_limit="61.1" upper_limit="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>STTU 10 - 10% Level PD-L1 : Met criteria 24 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="1"/>
                    <count group_id="O8" value="2"/>
                    <count group_id="O9" value="1"/>
                    <count group_id="O10" value="12"/>
                    <count group_id="O11" value="2"/>
                    <count group_id="O12" value="8"/>
                    <count group_id="O13" value="6"/>
                    <count group_id="O14" value="8"/>
                    <count group_id="O15" value="11"/>
                    <count group_id="O16" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O12" value="75.0" lower_limit="31.5" upper_limit="93.1"/>
                    <measurement group_id="O13" value="83.3" lower_limit="27.3" upper_limit="97.5"/>
                    <measurement group_id="O14" value="NA" lower_limit="NA" upper_limit="NA">Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O15" value="90.9" lower_limit="50.8" upper_limit="98.7"/>
                    <measurement group_id="O16" value="62.2" lower_limit="41.1" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Overall Survival Rate (OSR)</title>
        <description>The proportion of subjects surviving to time t, where t is a specific length of time, eg, 12 months, which was determined by the available data for final analysis and was documented in the DPP. The proportion was calculated by the product-limit method (Kaplan-Meier estimate), which takes into account censored data. The overall survival rate (OSR) for a subject was defined as the time from the date of first dose of study medication to the date of death for any cause. A subject who had not died was censored at last known date alive</description>
        <time_frame>2 years from first dose of treatment; Assessed up to September 2017</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>N3 60M Naive</title>
            <description>N3 = Nivolumab 3mg/kg;60M = 60 minute infusion; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O2">
            <title>N3 60M PROG</title>
            <description>N3 = Nivolumab 3mg/kg; 60M = 60 minute infusion;PROG = Anti-CTLA4 Progressed;</description>
          </group>
          <group group_id="O3">
            <title>N1 60M + I3 90M</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 90M = 90 minute infusion; 60M = 60 minute infusion</description>
          </group>
          <group group_id="O4">
            <title>N1 30M + I3 30M NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O5">
            <title>N3 30M NON-BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O6">
            <title>N1 30M + I3 30M BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O7">
            <title>N3 30M BM</title>
            <description>N3 = Nivolumab 3mg/kg; 30M = 30 minute infusion; BM = Brain metastases</description>
          </group>
          <group group_id="O8">
            <title>N1 + I3 NON-BM</title>
            <description>N1 = Nivolumab 1mg/kg; I3 = Ipilimumab 3 mg/kg; BM = Brain metastases</description>
          </group>
          <group group_id="O9">
            <title>N3 NAIVE</title>
            <description>N3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
          </group>
          <group group_id="O10">
            <title>All N3</title>
            <description>N3 = Nivolumab 3mg/kg</description>
          </group>
          <group group_id="O11">
            <title>N1 + I3</title>
            <description>All combination</description>
          </group>
          <group group_id="O12">
            <title>Total</title>
            <description>All treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Antitumor Activity of Nivolumab and Nivolumab in Combination With Ipilimumab as Measured by the Overall Survival Rate (OSR)</title>
          <description>The proportion of subjects surviving to time t, where t is a specific length of time, eg, 12 months, which was determined by the available data for final analysis and was documented in the DPP. The proportion was calculated by the product-limit method (Kaplan-Meier estimate), which takes into account censored data. The overall survival rate (OSR) for a subject was defined as the time from the date of first dose of study medication to the date of death for any cause. A subject who had not died was censored at last known date alive</description>
          <population>All treated participants</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="10"/>
                <count group_id="O8" value="52"/>
                <count group_id="O9" value="62"/>
                <count group_id="O10" value="106"/>
                <count group_id="O11" value="62"/>
                <count group_id="O12" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="79.0" upper_limit="97.6"/>
                    <measurement group_id="O2" value="90.8" lower_limit="77.3" upper_limit="96.4"/>
                    <measurement group_id="O3" value="85.2" lower_limit="65.2" upper_limit="94.2"/>
                    <measurement group_id="O4" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="90.0" lower_limit="47.3" upper_limit="98.5"/>
                    <measurement group_id="O6" value="90.0" lower_limit="47.3" upper_limit="98.5"/>
                    <measurement group_id="O7" value="80.0" lower_limit="40.9" upper_limit="94.6"/>
                    <measurement group_id="O8" value="92.3" lower_limit="80.8" upper_limit="97.0"/>
                    <measurement group_id="O9" value="90.2" lower_limit="79.6" upper_limit="95.5"/>
                    <measurement group_id="O10" value="90.5" lower_limit="83.0" upper_limit="94.8"/>
                    <measurement group_id="O11" value="91.9" lower_limit="81.7" upper_limit="96.6"/>
                    <measurement group_id="O12" value="91.0" lower_limit="85.5" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.3" lower_limit="70.2" upper_limit="93.1"/>
                    <measurement group_id="O2" value="78.9" lower_limit="63.3" upper_limit="88.4"/>
                    <measurement group_id="O3" value="81.5" lower_limit="61.1" upper_limit="91.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="90.0" lower_limit="47.3" upper_limit="98.5"/>
                    <measurement group_id="O6" value="90.0" lower_limit="47.3" upper_limit="98.5"/>
                    <measurement group_id="O7" value="80.0" lower_limit="40.9" upper_limit="94.6"/>
                    <measurement group_id="O8" value="90.4" lower_limit="78.4" upper_limit="95.9"/>
                    <measurement group_id="O9" value="85.3" lower_limit="73.6" upper_limit="92.0"/>
                    <measurement group_id="O10" value="82.6" lower_limit="73.8" upper_limit="88.6"/>
                    <measurement group_id="O11" value="90.3" lower_limit="79.7" upper_limit="95.5"/>
                    <measurement group_id="O12" value="85.5" lower_limit="79.2" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="58.5" upper_limit="85.7"/>
                    <measurement group_id="O2" value="71.7" lower_limit="55.5" upper_limit="82.8"/>
                    <measurement group_id="O3" value="81.5" lower_limit="61.1" upper_limit="91.8"/>
                    <measurement group_id="O4" value="88.0" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O5" value="90.0" lower_limit="47.3" upper_limit="98.5"/>
                    <measurement group_id="O6" value="90.0" lower_limit="47.3" upper_limit="98.5"/>
                    <measurement group_id="O7" value="68.6" lower_limit="30.5" upper_limit="88.7"/>
                    <measurement group_id="O8" value="84.6" lower_limit="71.6" upper_limit="92.0"/>
                    <measurement group_id="O9" value="76.6" lower_limit="63.7" upper_limit="85.4"/>
                    <measurement group_id="O10" value="74.6" lower_limit="64.9" upper_limit="81.9"/>
                    <measurement group_id="O11" value="85.5" lower_limit="74.0" upper_limit="92.2"/>
                    <measurement group_id="O12" value="78.7" lower_limit="71.6" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" lower_limit="55.7" upper_limit="83.7"/>
                    <measurement group_id="O2" value="64.5" lower_limit="48.2" upper_limit="76.9"/>
                    <measurement group_id="O3" value="77.6" lower_limit="56.8" upper_limit="89.3"/>
                    <measurement group_id="O4" value="88.0" lower_limit="67.3" upper_limit="96.0"/>
                    <measurement group_id="O5" value="80.0" lower_limit="40.9" upper_limit="94.6"/>
                    <measurement group_id="O6" value="90.0" lower_limit="47.3" upper_limit="98.5"/>
                    <measurement group_id="O7" value="68.6" lower_limit="30.5" upper_limit="88.7"/>
                    <measurement group_id="O8" value="82.6" lower_limit="69.3" upper_limit="90.6"/>
                    <measurement group_id="O9" value="73.1" lower_limit="59.8" upper_limit="82.6"/>
                    <measurement group_id="O10" value="69.5" lower_limit="59.5" upper_limit="77.5"/>
                    <measurement group_id="O11" value="83.8" lower_limit="72.0" upper_limit="91.0"/>
                    <measurement group_id="O12" value="74.9" lower_limit="67.5" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" lower_limit="34.3" upper_limit="65.4"/>
                    <measurement group_id="O2" value="46.8" lower_limit="31.1" upper_limit="61.1"/>
                    <measurement group_id="O3" value="69.6" lower_limit="48.3" upper_limit="83.5"/>
                    <measurement group_id="O4" value="58.5" lower_limit="36.4" upper_limit="75.2"/>
                    <measurement group_id="O5" value="58.3" lower_limit="23.0" upper_limit="82.1"/>
                    <measurement group_id="O6" value="77.1" lower_limit="34.5" upper_limit="93.9"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">N.C.: Not Calculated, fewer than 5 subjects at risk.</measurement>
                    <measurement group_id="O8" value="64.2" lower_limit="49.2" upper_limit="75.8"/>
                    <measurement group_id="O9" value="53.1" lower_limit="39.4" upper_limit="65.1"/>
                    <measurement group_id="O10" value="50.5" lower_limit="40.2" upper_limit="59.9"/>
                    <measurement group_id="O11" value="66.5" lower_limit="52.8" upper_limit="77.0"/>
                    <measurement group_id="O12" value="56.6" lower_limit="48.4" upper_limit="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From First dose up to 100 days after last dose of study drug, assessed up to September 2017 (approximately 59 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>UNPLANNED</title>
          <description>Unplanned</description>
        </group>
        <group group_id="E2">
          <title>NIV3-NAIVE</title>
          <description>Treatment Group: NIV3 = Nivolumab 3mg/kg; NAIVE = Anti-CTLA4 Naive</description>
        </group>
        <group group_id="E3">
          <title>NIV3-PROG</title>
          <description>Treatment Group: NIV3 = Nivolumab 3mg/kg; PROG = Anti-CTLA4 Progressed</description>
        </group>
        <group group_id="E4">
          <title>NIV1+IPI3 P2</title>
          <description>Treatment Group:NIV1 = Nivolumab 1mg/kg; IPI3 = Ipilimumab 3 mg/kg; P2 = Part 2</description>
        </group>
        <group group_id="E5">
          <title>NIV1+IPI3 P3</title>
          <description>Treatment Group: NIV1 = Nivolumab 1mg/kg; IPI3 = Ipilimumab 3 mg/kg; P3 = Part 3</description>
        </group>
        <group group_id="E6">
          <title>NIV3-Q2W P3</title>
          <description>Treatment Group: NIV3 = Nivolumab 3mg/kg; Q2W = every 2 weeks; P3 = Part 3</description>
        </group>
        <group group_id="E7">
          <title>IPI3-Q3W P3</title>
          <description>Treatment Group: IPI3 = Ipilimumab 3 mg/kg; Q3W = Every 3 weeks; P3 = Part 3</description>
        </group>
        <group group_id="E8">
          <title>NIV1+IPI3 P4</title>
          <description>Treatment Group: NIV1 = Nivolumab 1mg/kg; IPI3 = Ipilimumab 3 mg/kg; P4 = Part 4</description>
        </group>
        <group group_id="E9">
          <title>NIV3-Q2W P4</title>
          <description>Treatment Group: N3 = Nivolumab 3mg/kg; Q2W = Every 2 weeks; P4 = Part 4</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Intra-abdominal fluid collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Brain tumour operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Liver operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Endocrine disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hernia pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Localised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cortisol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Norovirus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oncologic complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Nipple pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Spermatic cord haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Facial wasting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Livedo reticularis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period  60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

